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ABSTRACT
Muscle sympathetic nerve activity was measured in nine acrome-
galic patients (age, 35 6 4 yr; body mass index, 28 6 2 kg/m2) and eight
healthy subjects (age, 32 6 3 yr; body mass index, 25 6 2 kg/m2) by
combining the forearm arterial-venous difference technique with the
tracer method [infusion of tritiated norepinephrine (NE)]. Muscle NE
release was quantified both at rest and during physiological hyper-
insulinemia while maintaining euglycemia (;90 mg/dL) by means of
the euglycemic clamp.
Arterial plasma NE was similar in the two groups at rest (197 6
28 and 200 6 27 pg/mL21) and slightly increased during insulin
infusion. Forearm NE release was 2.33 6 0.55 ngzliter21zmin21 in
healthy subjects and 2.67 6 0.61 ngzliter21zmin21 in acromegalic
subjects in the basal state and increased to a similar extent during
insulin infusion in both groups (3.13 6 0.71 and 3.32 6 0.75 ngzL21z
min21, P , 0.05 vs. basal), indicating a normal stimulatory effect of
insulin on muscle sympathetic activity. In contrast, insulin-stimu-
lated forearm glucose uptake was markedly lower in acromegalic
patients (2.3 6 0.4 mgzL21zmin21) than in control subjects (7.9 6 1.3
mgzL21zmin21, P , 0.001), indicating the presence of severe insulin
resistance involving glucose metabolism.
Our data demonstrate that patients with long-term acromegaly
have normal sympathetic activity in the skeletal muscle in the basal,
postabsorptive state and normal increments in NE spillover in re-
sponse to the sympatho-excitatory effect of insulin. Thus, the presence
of severe insulin resistance in acromegaly is not accounted for by
adrenergic mechanisms. (J Clin Endocrinol Metab 85: 3203–3207,
2000)
THE ELEVATED GH levels in patients with acromegalystrongly affect nutrient metabolism and contribute to pre-
mature mortality for cardiovascular disease (1, 2). The meta-
bolic abnormalities include hyperlipidemia (3), insulin resis-
tance with compensatory hyperinsulinemia (4–6), and in the
long term may lead to overt diabetes. Chronic GH hypersecre-
tion is also associated with cardiovascular changes, encompass-
ing myocardial hypertrophy, increased heart rate and cardiac
output, and decreased systemic vascular resistance, all of which
contribute to the so-called hyperkinetic heart syndrome (7, 8).
If acromegaly is untreated or treated unsuccessfully, the clinical
picture may progress toward cardiac dysfunction and, even-
tually, congestive heart failure (8). Arterial hypertension, fre-
quently observed in acromegalic patients, is a major determi-
nant of the deterioration of cardiac function (8). Whether the
metabolic and cardiovascular abnormalities present in acro-
megaly are entirely accounted for by GH hypersecretion itself
or are at least, in part, mediated by other factors is still uncertain.
Catecholamines may be a plausible candidate because
sympathetic overactivity causes insulin resistance (9, 10),
raises arterial blood pressure (11), and increases cardiovas-
cular mortality (12). Thus, a heightened sympathetic drive
could provide a pathogenetic basis for most of the clinical
features of acromegaly. To date, few studies have addressed
this issue. Some authors reported increased basal levels of
norepinephrine (NE) (13, 14), whereas others were unable to
confirm this finding (15, 16). A more recent study showed the
lack of circadian rhythm in catecholamine levels in active
acromegaly, which was restored after surgical correction
(17).
In the above studies, sympathetic nervous system (SNS)
activity was evaluated by measuring plasma catecholamine
levels. However, plasma NE is a poor index of sympathetic
tone because the NE level is determined not only by the rate
of its release but also by the rate at which it is removed from
the circulation. In addition, sympathetic activation is not
uniformly distributed in the body (i.e. in some districts the
SNS drive may be increased while, at the same time, it is
normal or even reduced in others) (18). Hence, the need to
adopt methodological approaches that allow estimation of
regional rather than global SNS activity.
The aim of the present study was to evaluate in patients
with acromegaly the sympathetic outflow in the skeletal
muscle, a site of key importance from both a metabolic and
a hemodynamic standpoint. To adequately explore this issue,
we combined the forearm perfusion technique with the in-
fusion of tritiated NE to measure NE release from the skeletal
muscle both in the basal state and during hyperinsulinemia,
which acts as a physiological sympatho-excitatory stimulus.
Subjects and Methods
Subjects
The study group consisted of eight normal subjects [age, 32 6 3 yr;
body mass index (BMI), 25 6 2 kg/m2] and nine patients with untreated
active acromegaly (age, 35 6 4 yr; BMI, 28 6 2 kg/m2). The relevant
characteristics of the subjects are given in Table 1. Diagnosis of acro-
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megaly was based on elevated GH levels not suppressible below 2 mg/L
by oral glucose test, high insulin-like growth factor I (IGF-I) levels for
age, signs and symptoms of the disease, and radiological evidence of
pituitary adenoma. The approximate duration of the disease was 9 6 2
yr, estimated by the clinical history and by comparison with old pho-
tographs of the patients. Thyroid, adrenal, and gonadal functions were
normal. Only one patient had mild hypertension according to the World
Health Organization criteria. None of the subjects was taking any med-
ication. Written informed consent was obtained from all participants.
The experimental protocol was approved by the Ethics Committee of the
University Federico II of Naples. The use of tracers for research purpose
in human subjects was approved by the National Health Authority.
Procedures
All subjects were studied in the postabsorptive state in the supine
position after a 12–14-h overnight fast. The forearm perfusion technique
(19) was performed as described previously (9). A plastic cannula was
introduced in a retrograde manner into a large antecubital vein and
threaded as deeply as possible for sampling of blood flowing primarily
from muscle tissue. A second cannula was inserted into the ipsilateral
brachial artery. This was used for infusion of indocyanine green dye
(Cardio-Green; Hynson, Westcott and Dunning, Baltimore, MD) to mea-
sure forearm blood flow as well as to sample arterial blood. A con-
tralateral arm vein was also cannulated for the infusion of test sub-
stances. During blood collection, a sphygmomanometer cuff placed
around the wrist was inflated 100 mm Hg above the systolic arterial
pressure to exclude the hand from the circulation. Soon after blood
collection, indocyanine green dye was infused through the arterial cath-
eter while keeping the cuff inflated around the wrist. After 4–5 min, two
consecutive blood samples were taken to measure the plasma concen-
tration of the dye.
After complete instrumentation, the subjects received iv a priming
dose (27 mCi) of L-(2,5,6-3H) NE (New England Nuclear, Boston, MA),
followed by a continuous infusion at the rate of 0.63 mCi/min through-
out the experimental period. The NE infusate was prepared with 0.9%
saline with the addition of ascorbic acid to prevent oxidation. After a
40-min equilibration period, two consecutive pairs of blood samples
were taken simultaneously from the arterial and venous catheters for
unlabeled and tritiated NE, serum insulin, and plasma glucose deter-
minations. Then, an infusion of regular insulin was started through the
peripheral vein at a rate of 1 mUzkg21zmin21 for 120 min to raise pe-
ripheral insulin concentration to postprandial levels. To maintain
plasma glucose at its basal value, a variable amount of glucose was also
infused. The glucose infusion rate was adjusted by measuring arterial
plasma glucose at 5–10-min intervals by means of a glucose analyzer
(Beckman Instruments, Fullerton, CA). Arterial and venous blood sam-
pling and blood flow measurements were performed at 90 and 120 min
during insulin infusion.
Analytical methods
Plasma glucose was determined on a Beckman glucose analyzer and
converted to blood glucose according to hematocrit. Serum insulin was
measured by RIA. Serum GH was measured by immunoradiometric
assay (HGH-CTK-IRMA; Sorin, Saluggia, Italy). The sensitivity of the
assay was 0.6 mU/L (1 mg/L corresponds to 3 mU/L). The intra- and
interassay coefficients of variation (CV) were 4.5% and 7.9%, respec-
tively. Plasma IGF-I was measured by immunoradiometric assay after
ethanol extraction using DSL kits (DSL, Webster, TX). The sensitivity of
the assay was 0.8 mg/L. The intra-assay CV were 3.4%, 3.0%, and 1.5%
for low, medium, and high point on the standard curve, respectively.
The interassay CV were 8.2%, 1.5%, and 3.7% for low, medium, and high
point of the standard curve. The plasma concentration of the green dye
was measured spectrophotometrically. Plasma catecholamines were
partially purified by batch alumina extraction (20), separated using
ion-pairing reverse-phase high-pressure liquid chromatography
(mBondapak C18-column, Powerline 600A chromatography system, and
WISP 700 as autoinjector; Waters Associates, Millipore, Milford, MA),
and quantified by a current produced on exposure of the column effluent
to oxidizing and then reducing potentials connected in series (Coulo-
chem 5100 A; ESA, Bedford, MA) (21). Recovery through the alumina
extraction step, calculated using dihydroxybenzylamine as an internal
standard, ranged between 60% and 70%, and each sample was corrected
for its recovery. The detection limit for NE was 3 pg. Intra- and interassay
variation coefficients were 4.1% and 9.8%, respectively.
Calculations
Forearm plasma flow was estimated by dividing the amount of in-
docyanine green dye infused by its concentration in the venous plasma
and converted to blood flow according to the hematocrit. The forearm
balance was calculated by multiplying the arterial-deep vein concen-
tration difference by the forearm blood (glucose) or plasma (NE) flow
and was normalized by the forearm volume in liters measured by water
displacement. However, in the case of NE, the forearm balance repre-
sents the algebraic sum of production and uptake of the neurotrans-
mitter, which have to be measured separately. The forearm fractional
extraction (FE) of 3H-NE was calculated by the equation FE 5 (A-V)/A;
where A and V are plasma concentrations of tritiated NE in arterial and
venous samples, respectively. NE clearance was obtained by multiply-
ing NE FE by the forearm plasma flow. Forearm NE uptake (FNU) was,
thus, obtained according to the formula: FNU 5 NE clearance 3 arterial
NE concentration. Once FNU was calculated, forearm NE release was
obtained subtracting FNU from the net NE balance. For each parameter,
the two observations made in the basal state (215 and 0 min) or during
insulin infusion (90 and 120 min) were averaged because, within each
condition, there was no statistical difference in the mean values of the
various parameters. Statistical analysis to test the effect of insulin was
performed by the paired t test since only two means were involved. The
unpaired t test was used to compare normal, with acromegalic subjects.
The results are presented as mean 6 se.
Results
Systolic and diastolic blood pressure were similar in the
two groups. Heart rate was 67 6 2 and 87 6 3 beats/min in
normal subjects and acromegalics, respectively (P , 0.0001).
In patients with acromegaly serum GH and IGF-I levels were
increased far above the normal values.
The data regarding forearm NE kinetics are summarized
in Table 2. Arterial plasma NE at rest was similar in control
(197 6 28 pg/mL21) and acromegalic subjects (200 6 27
pg/mL21), and it increased during insulin stimulation, al-
though the increase reached the statistical significance only
in the normal group (P , 0.05). NE FE was not different in
the two groups and remained substantially unchanged dur-
ing the hyperinsulinemic period. Forearm NE release at rest
was 2.33 6 0.55 ngzL21zmin21 in normal subjects and 2.67 6
0.61 ngzL21zmin21 in the acromegalic patients. During the
hyperinsulinemic period, forearm NE release increased to a
similar extent in the two groups (3.13 6 0.71 and 3.32 6 0.75
TABLE 1. Clinical characteristics of the subjects
Normals
(n 5 8)
Acromegalics
(n 5 9)
Age (yr) 32 6 3 35 6 4
Sex (M/F) 6/2 6/3
BMI (kg/m22) 25 6 2 28 6 2
Systolic blood pressure (mm Hg) 128 6 3 125 6 4
Diastolic blood pressure (mm Hg) 74 6 2 80 6 3
Heart rate (beats/min) 67 6 2 87 6 3
Forearm blood flow (ml/L21zmin21) 32 6 4 30 6 3
GH (mg/L) 28 6 11
IGF-I (mg/L) (100–500)a 660 6 80
Duration of disease (yr) 9 6 2
a Range of normal values in subjects aged 20–40 yr in our labo-
ratory.
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ngzL21zmin21 in normals and acromegalics, respectively).
The percentage increment was 35% in normals and 27% in
acromegalics.
As shown in Table 3, basal blood glucose levels were
similar in the two groups and remained virtually unchanged
during insulin infusion (CV, ,5%). Plasma insulin concen-
tration increased to ;50 mU/mL during insulin infusion in
both groups. In the basal state, forearm glucose uptake was
1.1 6 0.2 and 0.9 6 0.1 mgzL21zmin21 in controls and acro-
megalics, respectively, and, as expected, it increased during
insulin stimulation. However, the response observed in the
acromegalic patients was markedly blunted as compared
with that of control subjects. In normal subjects, there was a
7-fold increase in forearm glucose uptake (7.9 6 1.3
mgzL21zmin21) in response to insulin vs. a 2-fold increase in
acromegalics (2.3 6 0.4 mgzL21zmin21; P , 0.001).
Discussion
The present study was performed to assess the SNS ac-
tivity in the skeletal muscle of patients with acromegaly.
Previous attempts to explore this issue were based on plasma
NE determination or urinary catecholamine excretion (13–
17). Given the limitations inherent in the approaches used,
those studies cannot be considered conclusive. In the present
study, we reexamined the question by using the forearm
arterial-venous difference technique in conjunction with the
tracer approach to quantify regional NE release. Also, this
approach, referred to as NE spillover, provides an index of
nerve sympathetic activity because most of the neurotrans-
mitter released from the nerve endings undergoes local deg-
radation or reuptake before reaching the circulation—a pro-
cess not quantifiable yet. Despite this drawback, forearm NE
release is commonly used as a reliable index of SNS activity
because it closely reflects sympathetic nerve firing rates.
Our attention was focused on sympathetic outflow to the
skeletal muscle for several reasons. First, muscle vascular
bed is an important site of NE release. It has been estimated
that as much as 25% of the NE entering plasma in healthy
subjects is derived from muscle sympathetic nerves (18).
Second, muscle tissue is a major site where catecholamines
antagonize the biological action of insulin. Previous studies
have shown that epinephrine infusion (9, 22) as well as en-
dogenous sympathetic overactivity (10) are able to reduce
insulin-stimulated glucose disposal in forearm tissues, pre-
dominantly by b-adrenergic mechanisms. Based on these
considerations, we reasoned that an increased sympathetic
traffic in skeletal muscle tissue could provide useful insights
into the mechanisms underlying some abnormalities com-
monly associated with acromegaly, particularly insulin re-
sistance and the cardiovascular complications.
The present data demonstrate a normal sympathetic out-
flow to skeletal muscle in acromegalic patients in the basal
state. In this context, noteworthy is a previous study docu-
menting an increased muscle sympathetic activity in patients
with GH deficiency by direct recording of sympathetic nerve
action potentials at the level of the peroneal nerve (23). This
finding suggests that the GH/IGF-I axis is involved in the
regulation of the sympathetic drive and, altogether, the data
available would indicate that GH normally serves the func-
tion to restrain the SNS activity, at least with regard to the
skeletal muscle.
During hyperinsulinemia, NE release by the forearm skel-
etal muscle increased by ’30%, and the extent of this increase
was similar to that achieved in the control group. The pos-
sibility that SNS activity may have been differently stimu-
lated in the two groups during the first part of insulin in-
fusion cannot be excluded with certainty. It seems, however,
unlikely because insulin-induced SNS activation is not a
transient phenomenon, but rather lasts as long as the hor-
mone is infused. Thus, the increment in NE release docu-
mented in the last 30 min of insulin infusion closely reflects
the sympathetic response of muscle to insulin. Given the fact
TABLE 2. NE kinetics in the forearm skeletal muscle at rest and during insulin stimulation
Arterial plasma NE
(pg/mL21)
NE fractional
extraction (%)
Forearm NE release
(ngzL21zmin21)
Normals (n 5 8)
Rest 197 6 28 70 6 5 2.33 6 0.55
Insulin 265 6 28a 65 6 5 3.13 6 0.71a
Acromegalics (n 5 9)
Rest 200 6 27 60 6 2 2.67 6 0.61
Insulin 221 6 36 51 6 6 3.32 6 0.75a
a P , 0.05 as compared with baseline (paired t test).
TABLE 3. Glucose metabolism in the forearm skeletal muscle at rest and during insulin stimulation
Blood glucose
(mg/dL)
Plasma insulin
(mU/mL)
Forearm glucose uptake
(mgzL21zmin21)
Forearm blood flow
(mLzL21zmin21)
Normals (n 5 8)
Rest 88 6 2 5 6 1 1.1 6 0.2 32 6 4
Insulin 90 6 2 51 6 7 7.9 6 1.3a 35 6 5
Acromegalics (n 5 9)
Rest 90 6 5 7 6 1 0.9 6 0.1 30 6 3
Insulin 85 6 2 46 6 4 2.3 6 0.4a,b 34 6 2
a P , 0.0001 as compared with baseline.
b P , 0.001 as compared with controls (unpaired t test).
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that acromegaly is associated with a strong degree of insulin
resistance (6), one may speculate that these patients are ex-
posed daily to frequent bouts of sympathetic overactivity,
because of their exaggerated postprandial hyperinsulinemia.
It is conceivable that this chronic stimulation of the SNS
contributes in the long term to the higher prevalence of
cardiovascular complications in acromegaly.
The ability of insulin to activate the SNS is amply recog-
nized (24). Acute physiological hyperinsulinemia selectively
stimulates sympathetic nerve outflow to the skeletal muscle,
as determined by the measurement of muscle NE release (25)
or direct recording of muscle sympathetic nerve activity by
microneurography (26). Although the underlying mecha-
nisms are still poorly understood, the available evidence
suggests that the insulin sympathoexcitatory effect is medi-
ated by a central neural action involving hypothalamic nu-
clei. Actually, insulin receptors have been found in several
regions of the central nervous system, especially the median
hypothalamus (27). In addition, an intracerebroventricular
injection of insulin in rats, at a dose devoid of systemic
effects, results in increased sympathetic tone (28). Further
support to the role of central mechanisms comes from studies
by Lembo et al. (25), who showed that insulin infused directly
into the brachial artery has no effect on NE release and that
for a sympathetic activation to occur, insulin has to be in-
fused through a peripheral vein. Of great interest is also the
observation that dexamethasone is able to suppress insulin
sympathoexcitation, suggesting that the central action of in-
sulin is likely to involve the release of specific neuropeptides,
such as CRH (29). The finding of a normal sympathetic re-
sponse to insulin in acromegalic patients indirectly indicates
the absence of hypothalamic abnormalities concerning the
CRH-ACTH-cortisol axis, as also supported by the lack of
GH paradoxical response to CRH (30) and the normal cortisol
rhythm observed in these patients.
In contrast to the ability of insulin to activate the SNS,
its stimulatory effect on glucose metabolism is markedly
impaired in acromegalic patients. As shown in Table 3, in
these patients glucose uptake by the skeletal muscle was
3.5-fold lower than that observed in normal subjects at the
same insulin concentrations. The presence of insulin re-
sistance in acromegaly has long been recognized. Already
in the 1960s, Galbraith et al. (31) documented reduced
glucose uptake in forearm tissues during intra-arterial
insulin infusion in patients with acromegaly. Subse-
quently, Moller et al. (5) demonstrated that the impaired
muscle glucose metabolism is presumably due to a defect
in glucose oxidation consequent to the operation of glucose-
free fatty acid competition. In addition, a reduced suppressive
effect of insulin on hepatic glucose production has also been
documented in acromegaly (5).
The finding of a defect in both hepatic and extrahepatic
insulin action in acromegalic patients closely resembles the
effects of GH infusion in healthy volunteers. An iv 12-h
administration of GH blunted the ability of insulin to sup-
press hepatic glucose production and to stimulate peripheral
glucose disposal (32), in line with the view that the derange-
ment in glucose metabolism in acromegaly is, indeed, the
consequence of chronic GH excess. Support for this inter-
pretation is also provided by a recent study showing that
transgenic rabbits overexpressing GH develop not only ac-
romegaly but also hyperglycemia, hyperinsulinemia, and
hypertriglyceridemia—characteristic manifestations of insu-
lin resistance (33). The present observation of markedly im-
paired glucose disposal in the presence of normal sympa-
thetic activation by insulin speaks against a role of the SNS
in the insulin resistance of acromegaly, which is likely due
to GH interference with insulin-promoted cellular events.
The presence of selective resistance to insulin-mediated
glucose disposal, but not to the effect of insulin on the SNS
observed in acromegalic patients, is reminiscent of similar
data obtained by Tack et al. (34) in Type II diabetic patients,
in whom a marked resistance to the metabolic effects of
insulin is associated with a preserved insulin effect on the
SNS. This dissociation is not surprising considering that
insulin activates a complex array of pathways and medi-
ators. Therefore, it is possible that a defect in insulin sig-
naling may affect some, but not all, insulin actions. These
experimental data have their counterpart in some clinical
conditions, such as pseudoacromegaly, in which the met-
abolic effects of insulin are profoundly impaired whereas
the mitogenic action is preserved, causing an increased
tissue growth (35).
In conclusion, patients with long-term acromegaly show
normal sympathetic activity in the skeletal muscle in the
basal state and a normal response to the sympatho-excitatory
effect of insulin. Thus, the insulin resistance associated with
acromegaly is unrelated to adrenergic mechanisms.
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